- Home
- INKT vs SLGL Comparison
INKT vs SLGL Comparison
Compare INKT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- SLGL
- Stock Information
- Founded
- INKT 2017
- SLGL 1997
- Country
- INKT United States
- SLGL Israel
- Employees
- INKT N/A
- SLGL N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- SLGL Health Care
- Exchange
- INKT Nasdaq
- SLGL Nasdaq
- Market Cap
- INKT 48.7M
- SLGL 49.4M
- IPO Year
- INKT 2021
- SLGL 2018
- Fundamental
- Price
- INKT $15.83
- SLGL $27.50
- Analyst Decision
- INKT Buy
- SLGL
- Analyst Count
- INKT 3
- SLGL 0
- Target Price
- INKT $37.50
- SLGL N/A
- AVG Volume (30 Days)
- INKT 87.6K
- SLGL 33.8K
- Earning Date
- INKT 08-14-2025
- SLGL 08-15-2025
- Dividend Yield
- INKT N/A
- SLGL N/A
- EPS Growth
- INKT N/A
- SLGL N/A
- EPS
- INKT N/A
- SLGL N/A
- Revenue
- INKT N/A
- SLGL $23,931,000.00
- Revenue This Year
- INKT N/A
- SLGL N/A
- Revenue Next Year
- INKT N/A
- SLGL $31.17
- P/E Ratio
- INKT N/A
- SLGL N/A
- Revenue Growth
- INKT N/A
- SLGL 264.86
- 52 Week Low
- INKT $4.56
- SLGL $4.01
- 52 Week High
- INKT $76.00
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- INKT 53.11
- SLGL 74.68
- Support Level
- INKT $13.11
- SLGL $22.04
- Resistance Level
- INKT $15.26
- SLGL $30.00
- Average True Range (ATR)
- INKT 1.23
- SLGL 3.23
- MACD
- INKT 0.08
- SLGL 0.45
- Stochastic Oscillator
- INKT 85.26
- SLGL 84.44
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.